106 related articles for article (PubMed ID: 38728834)
1. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.
Boqaeid A; Layqah L; Alonazy A; Althobaiti M; Almahlawi AZ; Al-Roqy A; Baharoon O; Alsaeedi A; Shamou J; Baharoon S
J Infect Public Health; 2024 Jun; 17(6):1134-1141. PubMed ID: 38728834
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
4. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
5. The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy.
Al-Sohaim A; Bawazir AS; Al-Turki T; Alsafi EO; Al-Roqy A; Layqah L; Baharoone SA
Ann Saudi Med; 2021; 41(5):285-292. PubMed ID: 34618606
[TBL] [Abstract][Full Text] [Related]
6. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
[TBL] [Abstract][Full Text] [Related]
7. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
8. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
[TBL] [Abstract][Full Text] [Related]
9. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
[TBL] [Abstract][Full Text] [Related]
10. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
[TBL] [Abstract][Full Text] [Related]
11. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study.
Chiu YM; Tang CH; Hung ST; Yang YW; Fang CH; Lin HY
Scand J Rheumatol; 2017 May; 46(3):236-240. PubMed ID: 27766916
[TBL] [Abstract][Full Text] [Related]
12. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Tuberculosis Resulting From Reinfection in a Pediatric Patient Sequentially Treated With Etanercept and Adalimumab.
Guerrero-Laleona C; Calzada-Hernández J; Bustillo-Alonso M; Gil-Albarova J; Medrano-San Ildefonso M; Iglesias-Jiménez E; Noguera-Julian A
Pediatr Infect Dis J; 2017 Jan; 36(1):109-110. PubMed ID: 27749657
[TBL] [Abstract][Full Text] [Related]
16. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.
Lee SK; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA
Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990
[TBL] [Abstract][Full Text] [Related]
18. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
[TBL] [Abstract][Full Text] [Related]
19. Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.
González-Fernández MÁ; Villamañán E; Jiménez-Nácher I; Moreno F; Herrero A; Balsa A
Farm Hosp; 2019 Jan; 43(1):24-30. PubMed ID: 30624170
[TBL] [Abstract][Full Text] [Related]
20. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
